PURPOSE: To report on the planning procedure, quality control, and clinical implementation of intensity-modulated arc therapy (IMAT) delivering a simultaneous integrated boost (SIB) in patients with primary irresectable cervix carcinoma. PATIENTS AND METHODS: Six patients underwent PET-CT (positron emission tomography-computed tomography) and MRI (magnetic resonance imaging) before treatment planning. Prescription (25 fractions) was (1) a median dose (D(50)) of 62, 58 and 56 Gy to the primary tumor (GTV_cervix), primary clinical target volume (CTV_cervix) and its planning target volume (PTV_cervix), respectively; (2) a D(50) of 60 Gy to the PET-positive lymph nodes (GTV_nodes); (3) a minimal dose (D(98)) of 45 Gy to the planning target volume of the elective lymph nodes (PTV_nodes). IMAT plans were generated using an anatomy-based exclusion tool with the aid of weight and leaf position optimization. The dosimetric delivery of IMAT was validated preclinically using radiochromic film dosimetry. RESULTS: Five to nine arcs were needed to create valid IMAT plans. Dose constraints on D(50) were not met in two patients (both GTV_cervix: 1 Gy and 3 Gy less). D(98) for PTV_nodes was not met in three patients (1 Gy each). Film dosimetry showed excellent gamma evaluation. There were no treatment interruptions. CONCLUSION: IMAT allows delivering an SIB to the macroscopic tumor without compromising the dose to the elective lymph nodes or the organs at risk. The clinical implementation is feasible.
PURPOSE: To report on the planning procedure, quality control, and clinical implementation of intensity-modulated arc therapy (IMAT) delivering a simultaneous integrated boost (SIB) in patients with primary irresectable cervix carcinoma. PATIENTS AND METHODS: Six patients underwent PET-CT (positron emission tomography-computed tomography) and MRI (magnetic resonance imaging) before treatment planning. Prescription (25 fractions) was (1) a median dose (D(50)) of 62, 58 and 56 Gy to the primary tumor (GTV_cervix), primary clinical target volume (CTV_cervix) and its planning target volume (PTV_cervix), respectively; (2) a D(50) of 60 Gy to the PET-positive lymph nodes (GTV_nodes); (3) a minimal dose (D(98)) of 45 Gy to the planning target volume of the elective lymph nodes (PTV_nodes). IMAT plans were generated using an anatomy-based exclusion tool with the aid of weight and leaf position optimization. The dosimetric delivery of IMAT was validated preclinically using radiochromic film dosimetry. RESULTS: Five to nine arcs were needed to create valid IMAT plans. Dose constraints on D(50) were not met in two patients (both GTV_cervix: 1 Gy and 3 Gy less). D(98) for PTV_nodes was not met in three patients (1 Gy each). Film dosimetry showed excellent gamma evaluation. There were no treatment interruptions. CONCLUSION: IMAT allows delivering an SIB to the macroscopic tumor without compromising the dose to the elective lymph nodes or the organs at risk. The clinical implementation is feasible.
Authors: Arno J Mundt; Anthony E Lujan; Jacob Rotmensch; Steven E Waggoner; S Diane Yamada; Gini Fleming; John C Roeske Journal: Int J Radiat Oncol Biol Phys Date: 2002-04-01 Impact factor: 7.038
Authors: W A Peters; P Y Liu; R J Barrett; R J Stock; B J Monk; J S Berek; L Souhami; P Grigsby; W Gordon; D S Alberts Journal: J Clin Oncol Date: 2000-04 Impact factor: 44.544
Authors: Frederick B Stehman; Shamshad Ali; Henry M Keys; Laila I Muderspach; Weldon E Chafe; Donald G Gallup; Joan L Walker; Deborah Gersell Journal: Am J Obstet Gynecol Date: 2007-11 Impact factor: 8.661
Authors: Johannes C A Dimopoulos; Gertrude Schirl; Anja Baldinger; Thomas H Helbich; Richard Pötter Journal: Strahlenther Onkol Date: 2009-05-15 Impact factor: 3.621
Authors: Hilke Vorwerk; Daniela Wagner; Hans Christiansen; Clemens Friedrich Hess; Robert Michael Hermann Journal: Strahlenther Onkol Date: 2008-09-19 Impact factor: 3.621
Authors: Mark Rickhey; Zdenek Morávek; Christoph Eilles; Oliver Koelbl; Ludwig Bogner Journal: Strahlenther Onkol Date: 2010-05-21 Impact factor: 3.621